Exercise training in idiopathic pulmonary fibrosis

Size: px
Start display at page:

Download "Exercise training in idiopathic pulmonary fibrosis"

Transcription

1 Expert Review of Respiratory Medicine ISSN: (Print) (Online) Journal homepage: Exercise training in idiopathic pulmonary fibrosis Baruch Vainshelboim, Benjamin Daniel Fox, Jose Oliveira & Mordechai Reuven Kramer To cite this article: Baruch Vainshelboim, Benjamin Daniel Fox, Jose Oliveira & Mordechai Reuven Kramer (2015): Exercise training in idiopathic pulmonary fibrosis, Expert Review of Respiratory Medicine, DOI: / To link to this article: Accepted author version posted online: 15 Nov Published online: 07 Dec Submit your article to this journal Article views: 15 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at Download by: [ ] Date: 14 December 2015, At: 19:26

2 Review Exercise training in idiopathic pulmonary fibrosis Expert Rev. Respir. Med. Early online, 1 9 (2015) Baruch Vainshelboim *1,2, Benjamin Daniel Fox 1,3, Jose Oliveira 2 and Mordechai Reuven Kramer 1,3 1 Pulmonary Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel 2 Research Center in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Porto, Portugal 3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel *Author for correspondence: Tel.: /3 Fax: baruch.v1981@gmail.com Idiopathic pulmonary fibrosis (IPF) is a chronic devastating interstitial lung disease associated with exercise intolerance, dyspnea, hypoxemia, diminished quality of life and poor prognosis. A growing body of evidence with respect to short-term effects of exercise training has demonstrated clinical benefits in IPF patients. A recent systematic review showed significant improvements in 6-min walking distance, peak aerobic capacity, reduced dyspnea and improved quality of life. However, aspects of training programs, maintenance and predictors of improvement and the impact on prognosis need to be further explored. The aim of this paper was to comprehensively review the existing scientific literature regarding exercise training in patients with IPF and identify important gaps that should be studied in the future. KEYWORDS: Exercise tolerance 6-min walking distance dyspnea quality of life Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and ultimately fatal interstitial lung disease (ILD) occurring primarily in older adults.[1] The mortality rate in the United States in 2003 was 61.2 deaths per 1,000,000 in men and 54.5 per 1,000,000 in women, which is the most common cause of death in progressive lung disease (60% of deaths).[1] The etiology is usually unknown although several risk factors have been suggested, and typically it has a poor prognosis, with an estimated median survival range between 2 and 5 years from the time of diagnosis.[1 3] IPF is characterized by progressive pulmonary restriction, ventilatory insufficiency, dyspnea impaired gas exchange and hypoxemia, and diminished exercise capacity.[1,3,4] Patients with IPF are more breathless and tend to be less physically active to avoid such symptoms.[5,6] All these manifestations have a significant negative impact on functional capacity and health-related quality of life (HRQOL) in IPF patients.[3 6] Long-term effective treatment, apart from lung transplantation, is still limited for most IPF patients despite some encouraging recent findings with pharmacotherapy.[1,7 9] According to the latest American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines, pulmonary rehabilitation has only a weak level of recommendation for IPF patients based on the GRADE methodology for evidence quality. [1] The aim of this article was to comprehensively review the evidence of the wide impact of exercise training programs on patients with IPF and to address important research directions that should be focused on in the future. Pathophysiology of IPF Anatomically IPF manifests over several years by structural scar tissue within the lungs and pulmonary remodeling. This results in thickening of the alveolar walls and a characteristic appearance of honeycombing on high-resolution computed tomography.[3,10] In addition, parenchymal damage, interstitial fibrosis, collapse and apposition of alveolar walls, resulting in obliteration of alveolar lumina and distortion of normal lung architecture, have all been documented.[3,10] Resting pulmonary function Standard spirometry reveals decreased measures of forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV 1 ), while the ratio of FEV 1 /FVC remains normal (or increased), consistent with restrictive physiology as a consequence of reduced pulmonary compliance. This restrictive pattern is confirmed by reduced total lung capacity on lung volume body plethysmography measurements. [3,4] Gas exchange is impaired in IPF which / Taylor & Francis ISSN

3 Review Vainshelboim et al. can be demonstrated by reduced diffusion capacity for carbon monoxide, although maximal voluntary ventilation is usually normal.[3,4] In general, as the disease progresses, lung compliance decreases and lung volumes fall.[4] The resting arterial blood gas is usually normal or may reveal mild hypoxemia; however, breathing pattern is often rapid and shallow as the disease progresses.[4] Exercise capacity and limitation Exercise intolerance is a cardinal feature of IPF, associated with severe exertional dyspnea and fatigue and poor QOL.[11 13] Patients with ILD and IPF typically exhibit reduced maximal or peak aerobic capacity (VO 2peak ), peak work rate and submaximal exercise endurance compared with age- and sex-matched normal subjects.[12] Limitations to exercise capacity usually are multifactorial including abnormal pulmonary gas exchange, inefficient breathing mechanics, exercise induced hypoxemia, circulatory impairments and respiratory and skeletal muscle dysfunction. [4,11,12] A hallmark clinical sign among IPF patients is a decline in arterial O 2 pressure and arterial O 2 saturation (SaO 2 ) in response to exercise, which is mainly related to abnormalities in pulmonary gas exchange due to alveolar ventilation-perfusion (V A /Q) mismatching, oxygen diffusion limitation and low mixed venous oxygen content.[11,12] Ventilatory pattern is also abnormal in most IPF patients; however, breathing reserve in most patients is kept at normal levels.[11,12] Part of the elevated ventilatory drive in IPF during exercise relates to the increased dead space (VD) ventilation.[11,12] Although dyspnea is a predominant symptom in IPF patients, leg pain, chest discomfort and fatigue are common reasons for exercise test termination as well.[11,12] Several reports have suggested quadriceps weakness and peripheral muscle dysfunction in IPF patients.[14 16] Inflammation, hypoxemia, impaired oxidative capacity and high oxidative stress were proposed as contributing mechanisms in these studies.[14 16] In addition, patients can also be often bothered by a dry cough which interferes with daily activities. The onset of symptoms is slow, but symptoms become progressively worse over time.[3] The rationale for exercise training in IPF IPF is a chronic progressive lung disease that manifests in dyspnea and desaturation during physical effort, exercise intolerance and poor QOL.[1] Among other chronic lung diseases such as chronic obstructive pulmonary disease (COPD) patients, there is strong evidence for improvement following exercise interventions in exercise and functional capacities, level of dyspnea and HRQOL.[13,17 19] Despite the fact that IPF and COPD have a different pathophysiology, they share similar exercise and functional limitations in daily activities, dyspnea and poor QOL.[5,20] Furthermore, the American College of Sports Medicine stated in a position paper that exercise and physical activity are effective evidencebased strategies for limiting the progression of chronic diseases and disability in older adults.[21] Recently, the ATS/ERS documented that pulmonary rehabilitation is recommended for chronic lung diseases other than COPD, including ILD.[13] Furthermore, our team and others have shown significant short-term improvements following supervised exercise training among IPF patients.[13,20,22 24] These enhancements may have a significant clinical impact in helping IPF patients cope with functional activities of daily life and improve HRQOL.[22] In addition, IPF patients often present with comorbidities such as coronary arterial disease, chronic inflammation [1] and skeletal muscle dysfunction.[13] Exercise training has been established as an effective treatment for prevention and rehabilitation of those pathophysiologies in many well-designed large studies.[21,25] Finally, exercise capacity outcomes such as 6-min walk distance (6MWD) and VO 2peak are strong prognostic predictors for mortality in IPF [26 29] and are improved following exercise training programs with IPF patients.[16,22,23,30 38] It is possible that improvement in these outcomes following participation in exercise programs may also have some beneficial effect on prognosis in IPF; however, this has not yet been demonstrated. Effects of exercise training in IPF Exercise training has not been studied as extensively in IPF as in COPD patients.[5,13,20,24,39] However, a growing body of evidence has shown encouraging results with some health benefits following participation in these programs. [13,20,24,40] In the past few years, several retrospective, prospective and randomized controlled trials (RCTs) have demonstrated significant improvements in some outcomes after shortterm exercise programs among IPF patients.[5,13,20,24,39] Table 1 summarizes the exercise-training studies among patients with IPF. In general, studies showed that exercise training interventions are safe and effective treatment for ILD and IPF patients.[40] The exercise programs were undertaken for 4 12 weeks with 2 3 weekly exercise sessions of min. All training programs included aerobic endurance modality such as walking and cycling, whereas some programs also combined resistance and flexibility training, respiratory muscle training and breathing exercises.[16,22,23,30 38,41] Exercise tolerance Exercise intolerance is a cardinal manifestation of IPF associated with shortness of breath, poor QOL and mortality.[11 13,26,27] The majority of studies reported significant improvement in 6MWD following short-term exercise training interventions ranging from 15 to 81 m (Figure 1).[16,22,23,30 38] However, only few were conducted as RCTs [16,22,23,37] and the level of recommendation for pulmonary rehabilitation in the latest ATS/ERS guidelines is still weak.[1] The minimal clinical important difference (MCID) for 6MWD was established as m among patients with IPF [42]; most studies reported an improvement above this 2 Expert Rev. Respir. Med.

4 Exercise training in idiopathic pulmonary fibrosis Review Table 1. Exercise training studies in idiopathic pulmonary fibrosis patients. Study Number of Research Exercise Program s type Training modality IPF patients mode Jastrzebski et al.[41] 13 Prospective Twice weekly 4-week inpatient + 4 week home-based Leg cycling and respiratory muscle training Holland et al. [37] 34 RCT Twice weekly 8-week outpatient Nishiyama et al. [23] 28 RCT Twice weekly 10-week outpatient Ferreira et al. [34] 50 Retrospective 2 3 sessions a week, 6 8 weeks outpatient Ozalevli et al. [31] 17 Prospective Daily home-based sessions 12 weeks Swigris et al. [32] 14 Prospective 2 3 sessions a-week, 6 8 weeks outpatient Kozu et al. [30] 65 Prospective 2 sessions a week 8 weeks outpatients/home-based Walking + cycling and resistance training for lower body Walking + cycling and resistance exercises for peripheral muscles Walking + cycling, resistance and respiratory muscle training Walking, functional resistance training and breathing exercise Walking, cycling and resistance training Leg cycling and strength training walking and resistance training Rammaert et al. [33] 13 Prospective Daily home-based, 8 weeks Leg cycling Huppmann et al.[35] 202 Retrospective Inpatient 5 days/week, 4 weeks Walking, cycling and resistance training Arizono et al. [36] 48 Prospective 2 sessions a week, outpatient, 10 weeks Ryerson et al. [38] 22 Prospective 2 sessions a week, outpatient, 6 8 weeks Jackson et al. [16] 21 RCT 2 sessions a week, outpatient, 12 weeks Vainshelboim et al.[22] RCT: Randomized controlled trial. 34 RCT 2 sessions a week, outpatient, 12 weeks Leg cycling, resistance training and respiratory muscle training Walking, leg cycling and sitting elliptical Walking, leg cycling, resistance and flexibility Walking, leg cycling, stairs climbing, resistance and flexibility + breathing exercise Figure 1. Improvements in 6-min walking distance across exercise training studies in patients with idiopathic pulmonary fibrosis. MCID: Minimal clinical important difference; Δ6MWD: Pre- to postdifference of 6-min walking distance. Randomized controlled trials with mean difference of improvement between the exercise and the control groups. Retrospective study. Prospective noncontrolled study. 3

5 Review Vainshelboim et al. MCID threshold as presenting a clinically meaningful effect of exercise training interventions.[16,22,23,31 38] Few studies have also assessed exercise tolerance with metabolic variables using cardiopulmonary exercise testing.[16,22,36,37] While Arizono et al. [36] and Vainshelboim et al. [22] demonstrated significant improvements in peak work rate, VO 2peak and anaerobic threshold, Jackson et al. [16] showed only maintenance of steady state VO 2 and Holland et al. [37] failed to show any significant improvement in cardiopulmonary variables despite a significant enhancement of 35 m in the 6MWD test.[37] This inconsistency should be addressed in future large group studies in order to understand the physiological mechanisms that underline adaptation to training in IPF.[16,22,36,37] Dyspnea Dyspnea is a predominant symptom of IPF and clinically significant due to its strong association with exercise intolerance, poor HRQOL and mortality.[1,6,30,43,44] Reliefof dyspnea is therefore one of the important goals of IPF management.[43] Exercise training interventions in IPF have shown significant reduction in dyspnea sensation, although not all studies could demonstrate this benefit. [16,22,23,30 38] Evaluations of dyspnea were conducted using the Medical Research Council (MRC) dyspnea scale, [22,30 33,37,41] baseline dyspnea index,[16,23,41] Borg scale,[33,34,41] visual analogue scale [35] and University of California San Diego Shortness of Breath Questionnaire.[34,38] Itispossiblethattheusageofdifferent tools for dyspena assessment and varied training programs could have an impact on the variability in these studies findings.[16,22,23,30 38] Quality of life QOL is impaired in IPF patients with severe symptoms and declined functional capacity.[5,45] MostHRQOLdomains are poor,[5,45] and there are few therapies or other interventions that have shown efficacy to improve HRQOL in patients with IPF.[6] Swigriset al. [6] performed a systemic review of seven studies with 512 IPF patients that examined HRQOL.[6] The results of this review showed that IPF patients have significantly reduced HRQOL with a more pronounced repercussion in physical domains.[6] IPF patients suffer more breathlessness and tend to be less physical active in order to avoid such episodes which in turn influence their mobility and independence.[46] Usually they need more rest periods and longer recovery time after exercise.[46] In addition, IPF patients also report higher degrees of fatigue, exhaustion, anxiety, depression and fear.[5,45] There is a large heterogeneity in the evaluation of HRQOL in response to exercise training in IPF studies. The Saint George s Respiratory Questionnaire (SGRQ) and the Medical Outcome Short-Form (SF)-36 are the most common instruments that have been used, and recently were also validated with the MCID to assess improvement in HRQOL among IPF patients.[47 49] The MCID in IPF patients for the SGRQ was set to 5 8 points and to 2 4 points for the SF-36.[48] Several studies using SGRQ have shown significant improvement above the MCID (ranging from 5 to 11 points; a decrease in score denotes improvement) following supervised exercise training programs.[22,23,30,38,50] A few studies have also demonstrated enhancement above the MCID using SF-36 with a large distribution effect.[31,35] Yorke et al. developed an IPF-specific version of SGRQ. [51] However, to the best of our knowledge, this new instrument is yet to be implemented in exercise-based studies and its utility should be examined in future exercise training trials. The chronic respiratory disease questionnaire (CRDQ) has been used in one of the landmark randomized controlled studies of exercise training in ILD.[37] The CRDQ showed significant improvement in QOL, dyspnea and fatigue domains among ILD and IPF patients,[37] although to the best of our knowledge no MCID for CRDQ in IPF was established. Most studies showed a beneficial effect of exercise training in improving HRQOL in IPF patients,[22,23,30,31,33,35,37,38,50] although a few have reported no enhancement,[16,32,34,36] possibly due to differences in patient characteristics, training program modalities and nonspecific QOL instruments for IPF. Dowman et al. [40] recently published a Cochrane systematic review on pulmonary rehabilitation for ILD and subgroup of IPF. Their meta-analysis included five studies (86 participants who undertook pulmonary rehabilitation and 82 control participants).[40] The results for IPF patients showed significant improvements in 6MWD (36 meters, 95% CI 16 to 55), peak aerobic capacity (1.5 ml/kg/min, 95% CI ), reduced dyspnea ( 0.7 units, 95% CI 1.1 to 0.3) and improved QOL, (0.59 units, 95% CI 0.1 1).[40] These findings are consistent with the previous Cochrane review demonstrating clinical benefits of exercise training for ILD and IPF.[24] Skeletal muscle strength and endurance Only a few studies on exercise training in IPF patients have looked at the strength and endurance of peripheral muscles.[22,36] Arizono et al. showed significant improvement of hand grip and quadriceps strength using a dynamometer following 10 weeks of a pulmonary rehabilitation program.[36] Our group demonstrated significant improvement in a 30-sec-chair-stand-test (representing the functional strength-endurance capacity of lower limb muscles) after a 12-week exercise program.[22] Future studies need to address themuscularfitnesscomponentmoreextensivelyamongipf patients, due to its strong association with functional capacity and activity of daily living.[21,52] Physical activity Physical inactivity is identified by the World Health Organization as the fourth leading risk factor for global mortality.[53] Approximately 31% of adults are estimated to be physically inactive, contributing to 6% of all deaths.[53,54] In 4 Expert Rev. Respir. Med.

6 Exercise training in idiopathic pulmonary fibrosis Review 2008, physical inactivity alone caused 5.3 million premature deaths worldwide.[55] IPF manifests in severe signs and symptoms especially during physical exertion which is, in turn, associated with inactivity in order to avoid these episodes.[3,5] Inactivity among chronic respiratory disease patients is associated with poorer outcomes including higher mortality risk.[13] Nonetheless, the effect of participating in supervised exercise training or pulmonary rehabilitation programs on physical activity was not studied extensively among patients with IPF. Only two prospective studies examined the effect of short-term pulmonary rehabilitation programs on physical activity levels in IPF, with some conflicting results in the follow-up outcomes.[38,50] Both studies reported short-term improvement following the interventions; however, at 6-month follow-up Gaunaurd et al. [50] inarct showed deterioration in physical activity levels assessed by the International Physical Activity Questionnaire, while Ryerson et al. [38] in a prospective noncontrolled study demonstrated preservation of physical activity based on scores from the Rapid Assessment of Physical Activity questionnaire. Both studies have significant limitations in the accuracy of assessing physical activity by using subjective self-report questionnaires rather than more objective electronic devices. In addition, it is also possible that some bias effect exists in Ryerson s results due to the lack of a control group.[38] Wallaert et al. [56] using accelerometers for step counting demonstrated a 65% lower daily life physical activity level in patients with fibrotic idiopathic interstitial pneumonia compared to healthy sedentary controls.[56] Moreover,thisstudy also showed that among fibrotic idiopathic interstitial pneumonia patients, physical activity <3287 steps/day was associated with poorer prognosis and an almost three times higher risk for death (hazard ratio = 2.72).[56] Recently, Nakayama et al. [57] showed that disease severity as measured by blood biomarkers, the extent of honeycombing on high-resolution computed tomography, 6MWD and MRC dyspnea scale scores were associated with physical activity levels among 31 stable IPF patients.[57] More studies using accurate, objective, electronic instruments are warranted to ascertain the short- and long-term effects of participating in supervised exercise programs on physical activity levels in IPF patients. Predictors of benefit and response to exercise program Several authors working with rehabilitation of IPF patients attempted to identify predictors of benefits from exercise training programs.[30,58] It seems there is agreement with respect to the group of patients who benefit the most from these interventions.[30,58] Holland et al. [58] reported a greater improvement in mild disease severity among 25 IPF patients out of a group of 44 ILD patients based on FVC, level of desaturation and right ventricle systolic pressure.[58] This notion aligns with Kozu s et al. [30] findings among 65 IPF patients, demonstrating greater improvement in patients with mild to moderate MRC dyspnea compared to severe and very severe levels.[30] In contrast, Ryerson et al. [38] showed higher prerehabilitation functional capacity (as measured by a higher 6MWD) was associated with a lower improvement rate of this outcome in ILD and IPF patients.[38] This inconsistency may be related to methodological limitations and bias due to lack of intention to treat analysis for noncompleters and nonsurvivors in the latter study.[38] In addition, a large variation in response and adaptation to exercise training exist among IPF patients (Figure 1), and future exercise interventions should explore this issue more deeply. Methodology, program modalities and training types There is a large variability in exercise program modalities, research methodology and training types in IPF studies (Table 1). Although most studies conducted supervised outpatient-based programs,[16,22,23,30,32,34,36 38] few conducted home-based,[31,33,41] inpatient [35,41] or combined [30,41] programs. Most studies were prospective cohorts [16,22,23,30 33,36 38,41] and several were RCTs, [16,22,23,37] while few were retrospective.[34,35] In the majority of these studies, training programs combined aerobic exercise (walking or cycling or both) with resistance and flexibility exercises for peripheral skeletal muscles.[16,22,23,30 32,34 37] Some programs also included respiratory muscle training or breathing exercises.[22,31,34,36,41] Despite the fact that all these studies have reported some improvement in IPF patients following the exercise training period, inconsistency still exists with respect to the magnitude of improvement and different measures that have been used across studies.[16,22,23,30 38,41] Furthermore, most of these studies adopted the established COPD guidelines of exercise training in the pulmonary rehabilitation program. These guidelines might be less appropriate for IPF due to the different pathophysiological mechanisms of the exercise limitations, and therefore might consequently not deliver optimal exercise stimuli and adaption to training.[13,20] Recommended training variables such as frequency, intensity, type and time are unknown yet and also needs further investigation in large randomized controlled studies to optimize the exercise training programs for IPF. Long-term effect of exercise training Only few studies in IPF patients have conducted a follow-up reassessment after a completion of a short-term exercise program, and report some inconsistent results.[37,38,59] While Holland et al. [37] and Vainshelnoim et al. [59] showed nonsustained outcomes of exercise capacity, dyspnea and QOL at 6 and 11 months, respectively, Ryerson et al. [38] in contrast demonstrated preserved 6MWD, QOL, depression and physical activity levels at 6 month follow-up after 6 8 weeks of a pulmonary rehabilitation program.[38] Again this inconsistency is possibly related to methodological weaknesses in the Ryerson s study as discussed above.[38] Interestingly, in Vainshelboim s [59] study, despite a deterioration in 6MWD, VO 2peak, peak power and anaerobic threshold at 11-month follow-up, leg strength and QOL improvements were still preserved.[59] 5

7 Review Vainshelboim et al. Possibly a detraining effect in patients with IPF behaves differently across physiological and perceived outcomes, as was previously reported in young athletes, the elderly and COPD patients.[17,60 62] This issue too, should be ascertained in future research and maintenance of improvement strategies are warranted for IPF patients. Issues for consideration in the exercise program To the best of our knowledge no specific exercise guidelines exist for IPF.[20] Thus, issues presented in this chapter are based on observational reports of the published exercise training studies in IPF,[16,22,23,30 38,41] the pulmonary rehabilitation documents of several leading respiratory organizations [13,17,18] and our clinical experience and opinion. In general, exercise training seems to be safe and beneficial for IPF patients; [40] however, several issues should be considered in the management of exercise training programs in IPF (Table 2). Since patients with IPF tend to have accompanied comorbidities, such as coronary arterial disease, systemic and pulmonary hypertension, severe dyspnea and desaturation and arrhythmias during exercise,[1,3,4,12] it is important that baseline evaluation should be conducted. This may include a pulmonologist assessment, pulmonary function test and cardiopulmonary exercise testing to ensure the patient s safety before entering an exercise program.[13,63] Furthermore, IPF patients present exercise intolerance due to multifactorial limitations, including dyspnea and desaturation induced by physical demand.[11,12] It would be valuable to assess directly the electrocardiographic, hemodynamic and respiratory and gas exchange responses to evaluate the physiological limitations and the lowest level of oxygen saturation during incremental cardiopulmonary exercise testing. This would be in order to optimize personal exercise prescriptions and perform appropriate adjustments such as oxygen supplementation during the exercise sessions.[13] Oxygen supplementation seems to be necessary for hypoxemic IPF patients during exercise, as was recommended by the ATS/ERS guidelines.[1] To the best of our knowledge, in IPF there is no cutoff point of desaturation for oxygen delivery, although a threshold of SpO 2 > 90% was recommended for appropriated oxygenation in ILD,[39] based on COPD data.[64] Vainshelboim et al. [22] and Holland et al. [37] reported a threshold of SpO 2 < 88% and <85%, respectively, for oxygen supplementation during their exercise training sessions. The latter thresholds are probably more practical since IPF patients desaturate to much lower values compared to COPD patients.[65] Expert commentary and future research directions IPF is a chronic, progressive deadly lung disease usually presenting a poor prognosis.[1] We believe that it is important to address with large prospective trials whether rehabilitative exercise training can slow the progression of or change IPF s clinical course. Especially, knowledge whether exercise interventions can reduce the rate of exacerbations and mortality among patients with IPF will be highly valuable. We are entering into a new era Table 2. Issues for consideration in exercise program in idiopathic pulmonary fibrosis patients. Issue for consideration Safety Efficacy Baseline assessment using cardiopulmonary exercise testing Desaturation during exercise Cardiovascular signs: Arrhythmias: ventricular tachycardia, multifocal PVCs or triplets of PVCs, supraventricular tachycardia, heart block, new bundle branch block, or bradyarrhythmias. Hypotensive response: drop in SBP >10 mmhg from baseline Hypertensive response; SBP >250 mmhg or DBP >115 mmhg Symptoms: Chest pain Dizziness Syncope or near syncope Arrhythmias, ischemia and abnormal hemodynamics Monitoring of SpO 2 >85 88% Termination of exercise Termination of exercise Direct measure of aerobic capacity Detection of physiological limitations in exercise Accurate personalized exercise prescription Oxygen supplementation Interval trainingresistance training with adequate time for resaturation between the exercise bouts Further evaluation searching for reasons Further evaluation searching for reasons DBP: Diastolic blood pressure; SBP: Systolic blood pressure; SpO 2 : Oxygen saturation measured by pulse oximeter; PVC: Premature ventricular contraction. where IPF patients now have access to promising pharmacotherapy that has been recently approved by the Food and Drug Administration.[7 9] These drugs have shown benefits in slowing disease progression and increasing survival.[7 9] Patients lives can now be prolonged, meaning exercise and functional capacity and QOL have become even more important issues in order to maintain for longer the ability to cope with activities of daily life. Furthermore, in our opinion, it is valuable to deliver the rehabilitative exercise training as early as possible in IPF s disease course and to explore the optimal training modality for this group of patients. This is in order to more effectively target IPFs compromises and to maximize the improvement and maintenance of outcomes. In addition, a combination of the new pharmacotherapy with rehabilitative exercise training 6 Expert Rev. Respir. Med.

8 Exercise training in idiopathic pulmonary fibrosis Review should be empirically examined for any synergetic effect, and whether this could be further enhanced for the benefit of IPF patients. Five-year view We believe that in a few years, exercise training within pulmonary rehabilitation will be an evidence-based treatment for IPF patients and will become a part of standard care for IPF. Especially, a multidisciplinary comprehensive rehabilitation program will be integrated to patients treatment and management in collaboration with hospital and community centers. Conclusions IPF manifests in severe signs and symptoms, diminished exercise and functional capacity and poor QOL. The current published data demonstrate short-term clinical benefits of exercise training on exercise tolerance, dyspnea and QOL among patients with IPF. However, the optimal program variables and many other issues as described here are unknown yet and should be explored Key issues in future studies. Finally, the existing evidence of exercise training should be given good consideration to recommend exercise training based pulmonary rehabilitation programs for IPF patients. Acknowledgements The authors are grateful to Professor Anne Holland for her professional reviewing and important suggestions with this manuscript. The authors also express their gratitude to Ms. Dalia Dawn Orkin for her important English language contributions and editing services. Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Idiopathic pulmonary fibrosis (IPF) is chronic deadly lung disease with few effective therapeutic options. IPF manifests in pulmonary restriction, dyspnea, hypoxemia, exercise intolerance and poor quality of life. Exercise training studies in IPF showed clinical improvement in the short-term; however the benefits are usually not sustained after exercise program cessation. Exercise training improves 6-min walking distance ranging from 15 m to 81 m in IPF. Exercise training may reduce dyspnea, increase muscular fitness and enhance quality of life in IPF. Participating in a supervised exercise program can increase home-based physical activity in IPF. It is possible that at early stages of IPF with mild to moderate disease severity, patients respond better to exercise training interventions compared to more advanced or severe disease conditions. Optimal training modalities for IPF patients are yet to be established. Meticulous evaluation before starting the program and consideration during exercise sessions are important. References Papers of special note have been highlighted as: of interest of considerable interest 1. RaghuG,CollardHR,EganJJ,etal. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183 (6): Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to Am J Respir Crit Care Med. 2007;176(3): Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8. 4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1): Swigris JJ, Brown KK, Make BJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med. 2008;102 (12): Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60(7): King TE Jr., Bradford WZ, Castro- Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22): Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779): Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370 (22): Fukuda Y, Basset F, Ferrans VJ, et al. Significance of early intra-alveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis. Hum Pathol. 1995;26(1):

9 Review Vainshelboim et al. 11. Holland AE. Exercise limitation in interstitial lung disease mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7(2): Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med. 2004;25 (3): , v. 13. SpruitMA,SinghSJ,GarveyC,etal. An official American Thoracic Society/ European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13 e64. Recent American Thoracic Society/ European Respiratory Society position statement on pulmonary rehabilitation. 14. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest. 2005;127(6): Jackson R, Ramos C, Gupta C, et al. Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients. Respir Med. 2010;104 (12): Jackson RM, Gomez-Marin OW, Ramos CF, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. 2014;192(3): RiesAL,BauldoffGS,CarlinBW,etal. Pulmonary rehabilitation: joint ACCP/ AACVPR evidence-based clinical practice guidelines. Chest. 2007;131(5 Suppl):4S 42S. 18. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173(12): Burtin C, Hebestreit H. Rehabilitation in patients with chronic respiratory disease other than chronic obstructive pulmonary disease: exercise and physical activity interventions in cystic fibrosis and non-cystic fibrosis bronchiectasis. Respiration. 2015;89 (3): Kenn K, Gloeckl R, Behr J. Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis a review. Respiration. 2013;86(2): This is an important review paper of pulmonary rehabilitation in idiopathic pulmonary fibrosis. 21. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, et al. American College of Sports Medicine position stand. Exercise and physical activity for older adults. Med Sci Sports Exerc. 2009;41(7): Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration. 2014;88(5): This is an important randomized controlled study of pulmonary rehabilitation in idiopathic pulmonary fibrosis. 23. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3): This is an important randomized controlled study of pulmonary rehabilitation in idiopathic pulmonary fibrosis. 24. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. 2008;4:CD This is an important systematic review paper of exercise training in interstitial lung disease patients. 25. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/ European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9): e15 e du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(5): Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(5): Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2009;103(1): Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(6): Kozu R, Jenkins S, Senjyu H. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2011;16 (8): Ozalevli S, Karaali HK, Ilgin D, et al. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med. 2010;5(1): Swigris JJ, Fairclough DL, Morrison M, et al. Beneficial effects of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care. 2011;56(6): Rammaert B, Leroy S, Cavestri B, et al. Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. Rev Mal Respir. 2011;28(7): Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135 (2): Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013;42 (2): Arizono S, Taniguchi H, Sakamoto K, et al. Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis. Respir Care. 2013;59(7): Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6): This is an important randomized controled study of pulmonary rehabilitation in interstitial lung disease. 38. Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves longterm outcomes in interstitial lung disease: a prospective cohort study. Respir Med. 2014;108(1): Garvey C. Interstitial lung disease and pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2010;30(3): Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;10:CD This is a recent systematic review paper of pulmonary rehabilitation in interstitial lung disease. 41. Jastrzebski D, Gumola A, Gawlik R, et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol. 2006;57(Suppl 4): du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9): Expert Rev. Respir. Med.

10 Exercise training in idiopathic pulmonary fibrosis Review 43. Ryerson CJ, Donesky D, Pantilat SZ, et al. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage. 2012;43(4): Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40 (1): Belkin A, Swigris JJ. Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med. 2013;19(5): Swigris JJ, Stewart AL, Gould MK, et al. Patients perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005;3: Peng S, Li Z, Kang J, et al. Cross-sectional and longitudinal construct validity of the Saint George s Respiratory Questionnaire in patients with IPF. Respirology. 2008;13(6): Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104(2): Jones PW, Quirk FH, Baveystock CM. The St George s Respiratory Questionnaire. Respir Med. 1991;85 (Suppl B):25 31; discussion Gaunaurd IA, Gomez-Marin OW, Ramos CF, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. 2014;59 (12): Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George s Respiratory Questionnaire. Thorax. 2010;65(10): Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7): World Health Organization. Global recommendations on physical activity for health. Geneva: World Health Organization; Hallal PC, Andersen LB, Bull FC, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380(9838): Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380 (9838): Wallaert B, Monge E, Le Rouzic O, et al. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest. 2013;144(5): Nakayama M, Bando M, Araki K, et al. Physical activity in patients with idiopathic pulmonary fibrosis. Respirology. 2015;20 (4): Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012; 106(3): Vainshelboim B, Oliveira J, Fox BD, et al. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung. 2015;193(3): Lemmer JT, Hurlbut DE, Martel GF, et al. Age and gender responses to strength training and detraining. Med Sci Sports Exerc. 2000;32(8): Mujika I, Padilla S. Detraining: loss of training-induced physiological and performance adaptations. Part II: Long term insufficient training stimulus. Sports Med. 2000;30(3): Otsuka T, Kurihara N, Fujii T, et al. Effect of exercise training and detraining on gas exchange kinetics in patients with chronic obstructive pulmonary disease. Clin Physiol. 1997;17 (3): ACSM. ACSM s guidelines for exercise testing and prescription. Philadelphia, PA: Lippincott Wiliams & Wilkins; Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6): Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration. 2011;81 (3):

Key points. Educational aims

Key points. Educational aims Credit: Sheffield Teaching Hospitals NHS Foundation Trust Key points Exercise training has been proven to be a safe and effective behavioural intervention for prevention and rehabilitation of chronic conditions.

More information

Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: comparison with chronic obstructive pulmonary disease

Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: comparison with chronic obstructive pulmonary disease Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2017; 34; 283-289 Mattioli 1885 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: comparison

More information

Optimizing the Lung Transplant Candidate through Exercise Training. Lisa Wickerson BScPT, MSc Canadian Respiratory Conference April 25, 2014

Optimizing the Lung Transplant Candidate through Exercise Training. Lisa Wickerson BScPT, MSc Canadian Respiratory Conference April 25, 2014 Optimizing the Lung Transplant Candidate through Exercise Training Lisa Wickerson BScPT, MSc Canadian Respiratory Conference April 25, 2014 Conflicts of Interest None to declare Learning Objectives At

More information

פעילות גופנית במחלות נשימה כרוניות

פעילות גופנית במחלות נשימה כרוניות פעילות גופנית במחלות נשימה כרוניות ד"ר רונן בר-יוסף מכון ריאות ילדים מרפאת פעילות גופנית ותזונה נכונה בי"ח רות לילדים, רמב"ם פברואר 2014 במסגרת "רפואת ספורט" - שנה א' SPORTS MEDICINE Physical activity

More information

Division of Pulmonary, Critical Care, and Sleep Medicine, Jacksonville, FL. Department of Internal Medicine, Wichita, KS

Division of Pulmonary, Critical Care, and Sleep Medicine, Jacksonville, FL. Department of Internal Medicine, Wichita, KS in Patients with Respiratory Disease Furqan Shoaib Siddiqi, M.D. 1, Said Chaaban, M.D. 2, Erin Petersen, M.S.N., A.P.R.N. 3, K James Kallail, Ph.D. 2, Mary Hope, B.H.S., A.R.T., R.R.T., C.P.F.T. 3, Daniel

More information

DIAGNOSTIC NOTE TEMPLATE

DIAGNOSTIC NOTE TEMPLATE DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the

More information

The Importance of Pulmonary Rehabilitation

The Importance of Pulmonary Rehabilitation November 21, 2017 The Importance of Pulmonary Rehabilitation Presenter: George Pyrgos, MD 1 The importance of Pulmonary Rehabilitation George Pyrgos, MD Medical Director of the Angelos Lung Center at Medstar

More information

Wim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.

Wim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art. nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic

More information

Lessons to be learned from cardiopulmonary rehabilitation

Lessons to be learned from cardiopulmonary rehabilitation REHABILITATION AFTER CRITICAL ILLNESS: Lessons to be learned from cardiopulmonary rehabilitation Rik Gosselink, PT, PhD, FERS Faculty of Kinesiology and Rehabilitation Sciences University Hospitals Leuven,

More information

Massimiliano Polastri 1, Andrea Dell Amore 2, Giulia Zagnoni 1, Stefano Nava 3. Introduction

Massimiliano Polastri 1, Andrea Dell Amore 2, Giulia Zagnoni 1, Stefano Nava 3. Introduction Review Article Preoperative physiotherapy in subjects with idiopathic pulmonary fibrosis qualified for lung transplantation: implications on hospital length of stay and clinical outcomes Massimiliano Polastri

More information

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution

More information

Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic

Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO

More information

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing

More information

Outpatient Pulmonary Rehabilitation

Outpatient Pulmonary Rehabilitation Outpatient Pulmonary Rehabilitation Policy Number: 8.03.05 Last Review: 7/2017 Origination: 7/1995 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

Pulmonary rehabilitation in severe COPD.

Pulmonary rehabilitation in severe COPD. Pulmonary rehabilitation in severe COPD daniel.langer@faber.kuleuven.be Content Rehabilitation (how) does it work? How to train the ventilatory limited patient? Chronic Obstructive Pulmonary Disease NHLBI/WHO

More information

MEDICAL POLICY SUBJECT: PULMONARY REHABILITATION. POLICY NUMBER: CATEGORY: Therapy/ Rehabilitation

MEDICAL POLICY SUBJECT: PULMONARY REHABILITATION. POLICY NUMBER: CATEGORY: Therapy/ Rehabilitation MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

PULMONARY REHABILITATION Current Evidence and Recommendations

PULMONARY REHABILITATION Current Evidence and Recommendations PULMONARY REHABILITATION Current Evidence and Recommendations Overview Introduction to Pulmonary Rehabilitation Pathophysiolgy of Exercise Limitation Exercise training Current evidence for COPD Current

More information

OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO

OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index ACE inhibitors, see Angiotensin-converting enzyme inhibitors Aging

More information

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD) ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the

More information

Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis

Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan

More information

ILD and Pulmonary Rehabilitation

ILD and Pulmonary Rehabilitation ILD and Pulmonary Rehabilitation Chris Garvey FNP, MSN, MPA, MAACVPR Nurse Practitioner, UCSF Pulmonary Rehabilitation, Sleep Disorders, Division of Pulmonary Medicine PR - Background 1800 Exercise in

More information

호흡재활치료 울산의대서울아산병원 호흡기내과 이상도

호흡재활치료 울산의대서울아산병원 호흡기내과 이상도 호흡재활치료 울산의대서울아산병원 호흡기내과 이상도 Systemic (Extrapulmonary) effects in COPD Skeletal muscle dysfunction Osteoporosis Weight loss Sexual dysfunction Cardiovascular diseases (Gross et al., Curr Opin Pulm Med 2001;7:84)

More information

Outpatient Pulmonary Rehabilitation

Outpatient Pulmonary Rehabilitation Outpatient Pulmonary Rehabilitation Policy Number: 8.03.05 Last Review: 7/2018 Origination: 7/1995 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

OFEV MEDIA BACKGROUNDER

OFEV MEDIA BACKGROUNDER OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small

More information

POLICIES AND PROCEDURE MANUAL

POLICIES AND PROCEDURE MANUAL POLICIES AND PROCEDURE MANUAL Policy: MP230 Section: Medical Benefit Policy Subject: Outpatient Pulmonary Rehabilitation I. Policy: Outpatient Pulmonary Rehabilitation II. Purpose/Objective: To provide

More information

They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation

They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation Richard ZuWallack, MD Associate Chief, Pulmonary and Critical Care St. Francis Hospital, Hartford, CT Professor of Medicine

More information

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough

More information

The Prognostic Role of Ventilatory Inefficiency and Exercise Capacity in Idiopathic Pulmonary Fibrosis

The Prognostic Role of Ventilatory Inefficiency and Exercise Capacity in Idiopathic Pulmonary Fibrosis The Prognostic Role of Ventilatory Inefficiency and Exercise Capacity in Idiopathic Pulmonary Fibrosis Baruch Vainshelboim PhD, Jose Oliveira PhD, Benjamin Daniel Fox MBBS, and Mordechai Reuven Kramer

More information

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study 36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E

More information

Summary: Key Learning Points, Clinical Strategies, and Future Directions

Summary: Key Learning Points, Clinical Strategies, and Future Directions Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung

More information

Author s Accepted Manuscript

Author s Accepted Manuscript Author s Accepted Manuscript Low levels of physical activity predict worse survival to lung transplantation and poor early postoperative outcomesphysical activity level in lung transplantation James R.

More information

The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial

The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ thoraxjnl- 2016-208638). For numbered affiliations see end of article. Correspondence

More information

Cardiopulmonary Exercise Testing in Cystic Fibrosis

Cardiopulmonary Exercise Testing in Cystic Fibrosis Cardiopulmonary Exercise Testing in Cystic Fibrosis Owen Tomlinson MSc, AFHEA Children s Health & Exercise Research Centre University of Exeter James Shelley MSc Physical Activity Exchange Liverpool John

More information

Clinical exercise testing

Clinical exercise testing Basic principles of clinical exercise testing Clinical exercise testing This article is adapted from the on Basic principles of clinical exercise testing organised in Rome, March 2 4, 2006. Original slides,

More information

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life?

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Summary of the evidence located: According to the NICE guideline on Chronic Obstructive Pulmonary Disease

More information

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints

More information

Update on Pulmonary Rehabilitation Programme. HA Convention Dr. Wong WY, Ida Haven of Hope Hospital 8 May 2018

Update on Pulmonary Rehabilitation Programme. HA Convention Dr. Wong WY, Ida Haven of Hope Hospital 8 May 2018 Update on Pulmonary Rehabilitation Programme HA Convention Dr. Wong WY, Ida Haven of Hope Hospital 8 May 2018 Impacts of COPD to patients Increase dyspnoea Limitation of activity Decrease quality of life

More information

The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF

The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF Dr. Meir Mei-Zahav Kathy and Lee Graub CF Center Schneider CMCI 1 תאריך Exercise in CF You are probably quite sure that

More information

Exercise Stress Testing: Cardiovascular or Respiratory Limitation?

Exercise Stress Testing: Cardiovascular or Respiratory Limitation? Exercise Stress Testing: Cardiovascular or Respiratory Limitation? Marshall B. Dunning III, Ph.D., M.S. Professor of Medicine & Physiology Medical College of Wisconsin What is exercise? Physical activity

More information

The addition of non-invasive ventilation during exercise training in COPD patients. Enrico Clini and Michelle Chatwin

The addition of non-invasive ventilation during exercise training in COPD patients. Enrico Clini and Michelle Chatwin Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.

More information

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical

More information

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis Thorax Online First, published on March 22, 2012 as 10.1136/thoraxjnl-2011-201184 Interstitial lung disease < Additional materials are published online only. To view these files please visit the journal

More information

Cardiac Rehabilitation Program for LVAD Patients. Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR

Cardiac Rehabilitation Program for LVAD Patients. Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR Cardiac Rehabilitation Program for LVAD Patients Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR Left Ventricular Assist Devices (LVAD) Improved Survival Following LVAD Implantations

More information

Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis

Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline Online Supplement Ganesh Raghu, Bram Rochwerg, Yuan

More information

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies: Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the

More information

Development and validity testing of an IPF-specific version of the St George s Respiratory Questionnaire

Development and validity testing of an IPF-specific version of the St George s Respiratory Questionnaire < Additional data are published online only. To view these files please visit the journal online (http://thorax.bmj.com). 1 School of Nursing, Faculty of Health and Social Care, University of Salford,

More information

Oxygen therapy for interstitial lung disease: a systematic review

Oxygen therapy for interstitial lung disease: a systematic review REVIEW INTERSTITIAL LUNG DISEASE Oxygen therapy for interstitial lung disease: a systematic review Emily C. Bell 1, Narelle S. Cox 1,2,3, Nicole Goh 3,4,5, Ian Glaspole 5,6, Glen P. Westall 5,6, Alice

More information

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic

More information

Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis

Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis Page 1 of 6 AJRCCM Articles in Press. Published on 25-August-2017 as 10.1164/rccm.201708-1666ED Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary

More information

Testing Clinical Implications

Testing Clinical Implications Cardiopulmonary Exercise Testing Clinical Implications Dr Sahajal Dhooria Outline Basic concepts Case studies Recent advances in clinical applications of CPET Basic Concepts Exercise Any physical activity

More information

Evidence for early Pulmonary Rehabilitation following hospitalisation for exacerbation of COPD

Evidence for early Pulmonary Rehabilitation following hospitalisation for exacerbation of COPD Centre for Inflammation Research Evidence for early Pulmonary Rehabilitation following hospitalisation for exacerbation of COPD Pulmonary Rehabilitation Clinicians Day Roberto A. Rabinovich ELEGI/Colt

More information

Outpatient Pulmonary Rehabilitation. Description

Outpatient Pulmonary Rehabilitation. Description Subject: Outpatient Pulmonary Rehabilitation Page: 1 of 16 Last Review Status/Date: March 2015 Outpatient Pulmonary Rehabilitation Description Pulmonary rehabilitation (PR) is a multidisciplinary approach

More information

Contemporary Clinical Trials Communications

Contemporary Clinical Trials Communications Contemporary Clinical Trials Communications 3 (2016) 80e85 Contents lists available at ScienceDirect Contemporary Clinical Trials Communications journal homepage: www.elsevier.com/locate/conctc Idiopathic

More information

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust Interstitial Lung Disease (ILD) Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust The views expressed in this presentation are those of the speaker and are not necessarily those

More information

Exercise Progression for the Cardiac, Pulmonary & PAD Patient

Exercise Progression for the Cardiac, Pulmonary & PAD Patient Exercise Progression for the Cardiac, Pulmonary & PAD Patient Thomas P. Mahady MS CSCS CCRP Hackensack University Medical Center Hackensack Meridian Health Learning Objectives The Art of Exercise Prescription.

More information

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to

More information

Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital

Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled

More information

Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis

Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASES Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis Brett Ley 1, Williamson Z. Bradford 2, Derek Weycker 3, Eric Vittinghoff

More information

Idiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis Eur Respir J 2010; 36: 1067 1072 DOI: 10.1183/09031936.00152609 CopyrightßERS 2010 A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis O. Nishiyama*,", H. Taniguchi*,

More information

Pulmonary Rehabilitation Focusing on Rehabilitative Exercise Prof. Richard Casaburi

Pulmonary Rehabilitation Focusing on Rehabilitative Exercise Prof. Richard Casaburi Pulmonary Rehabilitation 1 Rehabilitation Clinical Trials Center Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance, California, USA Historical perspective on rehabilitative

More information

Management of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures

Management of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board

More information

The Value of Exercise in the Cystic Fibrosis Clinic. Dr Patrick J Oades

The Value of Exercise in the Cystic Fibrosis Clinic. Dr Patrick J Oades The Value of Exercise in the Cystic Fibrosis Clinic Dr Patrick J Oades WHO Global recommendations for physical activity and health 2010. Geneva: WHO Library Cataloguing-in-Publication Data. [ISBN: 978

More information

The Art and Science of Pulmonary Rehab. Pam Haines, RCP Cardiopulmonary Rehab Manager

The Art and Science of Pulmonary Rehab. Pam Haines, RCP Cardiopulmonary Rehab Manager The Art and Science of Pulmonary Rehab Pam Haines, RCP Cardiopulmonary Rehab Manager ATS/ERS Statement on PR As defined by the 2013 ATS/ERS Statement on Pulmonary Rehabilitation, PR is a comprehensive

More information

Pulmonary Rehabilitation in COPD-An Important Non-pharmacological Treatment

Pulmonary Rehabilitation in COPD-An Important Non-pharmacological Treatment 122 Review Article Pulmonary Rehabilitation in COPD-An Important Non-pharmacological Treatment Department of Adult Nursing, Maharajgunj Nursing Campus, Institute of Medicine, Tribhuvan University, Kathmandu,

More information

Pirfenidone: an update on clinical trial data and insights from everyday practice

Pirfenidone: an update on clinical trial data and insights from everyday practice REVIEW IDIOPATHIC PULMONARY FIBROSIS Pirfenidone: an update on clinical trial data and insights from everyday practice Michael Kreuter 1,2 Affiliations: 1 Dept of Pneumology and Respiratory Critical Care

More information

OHTAC Recommendation: Chronic Obstructive Pulmonary Disease (COPD) Ontario Health Technology Advisory Committee

OHTAC Recommendation: Chronic Obstructive Pulmonary Disease (COPD) Ontario Health Technology Advisory Committee OHTAC Recommendation: Chronic Obstructive Pulmonary Disease (COPD) Ontario Health Technology Advisory Committee March 2012 Background The Chronic Obstructive Pulmonary Disease Mega-Analysis series is made

More information

Chapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension

Chapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir

More information

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.

More information

Mobilization and Exercise Prescription

Mobilization and Exercise Prescription 1 Clinicians can use this job aid as a tool to guide them through mobilization and exercise prescription with patients who have cardiopulmonary conditions. Mobilization and Exercise Prescription Therapy

More information

Endurance time is the most responsive exercise measurement in idiopathic

Endurance time is the most responsive exercise measurement in idiopathic Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis Shinichi Arizono PT PhD 1, 3, 8, Hiroyuki Taniguchi MD PhD 2, Koji Sakamoto MD PhD 4, Yasuhiro Kondoh MD PhD

More information

Manuscript Draft. Title: What if we made stratified medicine work for patients?

Manuscript Draft. Title: What if we made stratified medicine work for patients? Respiratory Medicine Elsevier Editorial System(tm) for The Lancet Manuscript Draft Manuscript Number: Title: What if we made stratified medicine work for patients? Article Type: Comment Keywords: stratified

More information

NINTEDANIB MEDIA BACKGROUNDER

NINTEDANIB MEDIA BACKGROUNDER NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule

More information

Investor Update. Services. Investor Relations team Send . Basel, 24 May Subscribe to Roche news

Investor Update. Services. Investor Relations team Send  . Basel, 24 May Subscribe to Roche news Investor Update Basel, 24 May 2017 New data at ATS add to the body of evidence for Roche s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet

More information

[ Original Research Diffuse Lung Disease ]

[ Original Research Diffuse Lung Disease ] [ Original Research Diffuse Lung Disease ] Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis Christopher

More information

Cardiac rehabilitation and physical activity

Cardiac rehabilitation and physical activity Cardiac rehabilitation and physical activity Mind the heart and the brain KATARINA HEIMBURG Skane University Hospital in Lund Lund University Cardiac rehabilitation The coordinated sum of interventions

More information

Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature

Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature Additional data are published online only. To view the files please visit the journal online (http://dx.doi.org/10. 1136/thoraxjnl-2012-202040). 1 Department of Palliative Medicine, Royal Marsden and Royal

More information

Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial

Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial ERJ Express. Published on February 25, 2016 as doi: 10.1183/13993003.01683-2015 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial

More information

Respiratory Pathophysiology Cases Linda Costanzo Ph.D.

Respiratory Pathophysiology Cases Linda Costanzo Ph.D. Respiratory Pathophysiology Cases Linda Costanzo Ph.D. I. Case of Pulmonary Fibrosis Susan was diagnosed 3 years ago with diffuse interstitial pulmonary fibrosis. She tries to continue normal activities,

More information

Use of the 15-steps climbing exercise oximetry test in patients with idiopathic pulmonary fibrosis

Use of the 15-steps climbing exercise oximetry test in patients with idiopathic pulmonary fibrosis Respiratory Medicine (28) 12, 18 188 Use of the 15-steps climbing exercise oximetry test in patients with idiopathic pulmonary fibrosis Victorya Rusanov a, David Shitrit b, Ben Fox b, Anat Amital b, Nir

More information

Effects of Physical Activity and Sleep Quality in Prevention of Asthma

Effects of Physical Activity and Sleep Quality in Prevention of Asthma Journal of Physiology and Pharmacology Advances Effects of Physical Activity and Sleep Quality in Prevention of Asthma Tartibian B., Yaghoobnezhad F. and Abdollahzadeh N. J Phys Pharm Adv 2014, 4(5): 356-359

More information

Bi-Level Therapy: Boosting Comfort & Compliance in Apnea Patients

Bi-Level Therapy: Boosting Comfort & Compliance in Apnea Patients Bi-Level Therapy: Boosting Comfort & Compliance in Apnea Patients Objectives Describe nocturnal ventilation characteristics that may indicate underlying conditions and benefits of bilevel therapy for specific

More information

Outpatient Pulmonary Rehabilitation

Outpatient Pulmonary Rehabilitation Protocol Outpatient Pulmonary Rehabilitation (80305) Medical Benefit Effective Date: 07/01/15 Next Review Date: 03/18 Preauthorization No Review Dates: 03/07, 05/08, 05/09, 03/10, 03/11, 03/12, 03/13,

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

Pulmonary Function Testing. Ramez Sunna MD, FCCP

Pulmonary Function Testing. Ramez Sunna MD, FCCP Pulmonary Function Testing Ramez Sunna MD, FCCP Lecture Overview General Introduction Indications and Uses Technical aspects Interpretation Patterns of Abnormalities When to perform a PFT 1. Evaluation

More information

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis The new england journal of medicine original article A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Talmadge E. King, Jr., M.D., Williamson Z. Bradford, M.D., Ph.D., Socorro

More information

Workshop: Pulmonary rehabilitation and NIV

Workshop: Pulmonary rehabilitation and NIV Workshop: Pulmonary rehabilitation and NIV Jean-Christian Borel INSERM U 1042, HP2 Laboratory, Université Joseph Fourier, Faculté de Médecine, Grenoble, France, AGIRadom, Research and Development department,

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

Idiopathic pulmonary fibrosis (IPF) is a

Idiopathic pulmonary fibrosis (IPF) is a Eur Respir J 2011; 38: 176 183 DOI: 10.1183/09031936.00114010 CopyrightßERS 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema S.L. Schmidt*,

More information

FOLLOW-UP MEDICAL CARE OF SERVICE MEMBERS AND VETERANS CARDIOPULMONARY EXERCISE TESTING

FOLLOW-UP MEDICAL CARE OF SERVICE MEMBERS AND VETERANS CARDIOPULMONARY EXERCISE TESTING Cardiopulmonary Exercise Testing Chapter 13 FOLLOW-UP MEDICAL CARE OF SERVICE MEMBERS AND VETERANS CARDIOPULMONARY EXERCISE TESTING WILLIAM ESCHENBACHER, MD* INTRODUCTION AEROBIC METABOLISM ANAEROBIC METABOLISM

More information

A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD

A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD RESPIRATORY MEDICINE (2001) 95, 71 77 doi:10.1053/rmed.2000.0976, available online at http://www.idealibrary.com on A comparison of three disease-specific and two generic health-status measures to evaluate

More information

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis

Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives

More information

New Horizons The Future of IPF and ILD

New Horizons The Future of IPF and ILD New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco

More information

Conflicts of interest. Objec5ves / Outline. Pulmonary rehabilita5on. Pulmonary rehabilita5on in COPD. Pulmonary rehabilita5on in COPD 11/26/13

Conflicts of interest. Objec5ves / Outline. Pulmonary rehabilita5on. Pulmonary rehabilita5on in COPD. Pulmonary rehabilita5on in COPD 11/26/13 Conflicts of interest UBC I have no conflicts of interest related to this presenta5on Treatment op+ons From a global perspec+ve: Non- pharmaceu+cal treatments Pulmonary Fibrosis Founda5on Summit La Jolla,

More information

Cardiopulmonary Stress Testing: Beyond Transplant Evaluation

Cardiopulmonary Stress Testing: Beyond Transplant Evaluation Cardiopulmonary Stress Testing: Beyond Transplant Evaluation Ross Arena, PhD, PT, FAHA, FESC, FACSM Professor and Head College of Applied Health Sciences University of Illinois at Chicago Cardio- Pulmonary

More information

Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis

Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Respirology (2008) 13, 394 399 doi: 10.1111/j.1440-1843.2007.01205.x ORIGINAL ARTICLE Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Osamu NISHIYAMA, 1 Yasuhiro KONDOH,

More information

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test? Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard

More information

5/7/2017. Disclosures. What is CPET? Outline. VQ Matching. At a basic level. None. Functional ability

5/7/2017. Disclosures. What is CPET? Outline. VQ Matching. At a basic level. None. Functional ability Disclosures Cardio-Pulmonary Exercise Testing None Madhav Swaminathan, MD, MMCi Professor of Anesthesiology Duke University Health System Durham, NC Outline What is CPET? Overview: What it is Rationale:

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

Course Handouts & Disclosure

Course Handouts & Disclosure COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation

More information